Nucleobase adduct-containing metabolites are MR1 ligands that stimulate self-reactive MR1T cells

MR1T lymphocytes are a recently identified population of T cells that recognize unknown self-antigens presented by the non-polymorphic MHC-I-related molecule, MR1. MR1T cells can kill tumor cells and modulate the functions of other immune cells with promising therapeutic applications. By integrating genetic, pharmacological and biochemical approaches we identified carbonyl stress and alterations of nucleobase metabolism in tumor target cells that promote recognition by MR1 T cells. We dissected these pathways and found that nucleobase adduct-containing metabolites are self-antigens stimulating MR1T cells. Several nucleobase adducts are presented by MR1 molecules and stimulate individual MR1T cells. Our data suggest that MR1T cells are surveyor of cellular metabolic alterations occurring in conditions of metabolic stress, such as cancer, and lay the groundwork for the development of novel HLA-unrestricted T cell-based therapies. ### Competing Interest Statement A.V., A.C., Q.Y., J.S., M.L., L.M., G.D.L. are listed as inventors in patent applications related to MR1T-based cancer treatment. A.V., A.C., Q.Y., J.S., L.M., G.D.L. are shareholders of Matterhorn Biosciences AG. All other authors declare no competing interests.